What is the appropriate management for a patient with measles, including isolation, supportive care, vitamin A therapy, and post‑exposure prophylaxis?

Management of Measles

For a patient with confirmed or suspected measles, immediately isolate the patient in an airborne-infection isolation room, administer vitamin A supplementation (200,000 IU orally for patients ≥12 months, 100,000 IU for infants <12 months), provide supportive care for complications, and implement post-exposure prophylaxis for susceptible contacts using MMR vaccine within 72 hours or immune globulin within 6 days of exposure. 1

Immediate Isolation and Infection Control

Airborne precautions must be implemented immediately upon suspicion of measles:

• Place the patient in a negative-pressure airborne-infection isolation room with the door closed 2
• All healthcare personnel entering the room must wear N95 respirators (or equivalent), regardless of their immunity status 1
• The patient remains infectious from 4 days before rash onset through 4 days after rash appearance 2
• Healthcare workers without documented measles immunity must be excluded from work from day 5 through day 21 after exposure 1
• If an exposed worker develops measles, exclude them until at least 4 days after rash onset 1

Critical pitfall: Do not delay isolation while awaiting laboratory confirmation—clinical suspicion alone warrants immediate airborne precautions. 3

Mandatory Vitamin A Supplementation

All children with clinical measles must receive vitamin A supplementation, as this is the only evidence-based intervention proven to reduce measles mortality:

Standard Dosing Protocol

• Children ≥12 months (including adults): 200,000 IU orally on day 1 1, 2
• Infants <12 months: 100,000 IU orally on day 1 1, 2

Enhanced Two-Dose Regimen for Complicated Measles

• Administer an identical second dose on day 2 when any of the following complications are present: pneumonia, otitis media, croup, diarrhea with moderate or severe dehydration, or neurological problems 1
• This two-dose regimen reduces overall mortality by 64% (RR 0.36), pneumonia-specific mortality by 67% (RR 0.33), and mortality in children <2 years by 82% (RR 0.18) 1, 4

Extended Protocol for Vitamin A Deficiency with Eye Manifestations

• When eye signs are present (xerosis, Bitot's spots, keratomalacia, or corneal ulceration): give 200,000 IU on day 1, another 200,000 IU on day 2, and a third 200,000 IU dose 1-4 weeks later 1
• Infants <12 months receive half these doses (100,000 IU per dose) 1

Evidence strength: The two-dose vitamin A regimen has the strongest evidence, particularly when using water-based formulations, which showed an 81% mortality reduction compared to 48% with oil-based preparations. 4

Supportive Care and Complication Management

Measles treatment is primarily supportive, with aggressive management of secondary bacterial infections:

Respiratory Complications

• Pneumonia or acute lower respiratory infection: Initiate standard antibiotic therapy according to local protocols immediately 1
• Croup: Provide standard croup management; vitamin A reduces croup incidence by 47% (RR 0.53) 4
• Monitor for respiratory distress: markedly raised respiratory rate, grunting, intercostal recession, breathlessness with chest signs, or cyanosis 1

Gastrointestinal Complications

• Diarrhea: Use oral rehydration therapy (ORT) promptly 1
• Do not use anti-diarrheal medications 5
• Vitamin A reduces diarrhea duration by approximately 2 days (WMD -1.92 days) 4
• For infants <6 months with severe dehydration and inability to feed: administer isotonic crystalloid at 20 mL/kg IV boluses, repeating until vital signs normalize 5

Other Complications

• Otitis media: Provide appropriate antibiotic therapy 1
• Fever: Administer acetaminophen or ibuprofen as needed; aspirin is contraindicated in children <16 years 1
• Nutritional support: Assess and monitor nutritional status; enroll in supplemental feeding programs when indicated 1

Common pitfall: Diarrhea is the most frequent complication, followed by otitis media and bronchopneumonia, with encephalitis occurring in approximately 1 per 1,000 cases. 1 Do not underestimate the severity of gastrointestinal fluid losses.

Diagnostic Confirmation

Laboratory confirmation should be obtained during the first clinical encounter, but treatment should not be delayed:

• Collect serum for measles-specific IgM antibody testing during the first visit 2
• If IgM is negative within 72 hours of rash onset, obtain a second specimen at least 72 hours after rash onset, as IgM may not be detectable early 2
• IgM peaks approximately 10 days after rash onset and remains detectable for at least 1 month 2
• Contact local or state health department immediately—one confirmed case constitutes an urgent public health situation 2

Post-Exposure Prophylaxis

The choice between MMR vaccine and immune globulin depends on timing, patient characteristics, and contraindications:

MMR Vaccine (Preferred for Most Susceptible Contacts)

• Timing: Administer within 72 hours of exposure for maximum effectiveness 6, 1
• Eligible populations: Susceptible contacts ≥6 months old without contraindications 1
• Mechanism: May prevent infection or attenuate disease severity if given promptly 2
• Exclusions: Pregnant women, immunocompromised individuals, and those with vaccine contraindications 1

Immune Globulin (IG) Prophylaxis

For general susceptible contacts (when vaccine is contraindicated or timing exceeds 72 hours):

• Dose: 0.25 mL/kg IM (maximum 15 mL) 6, 1
• Timing: Administer within 6 days of exposure 6, 1
• Indications: Infants ≤12 months, pregnant persons, and those with vaccine contraindications 1

For immunocompromised susceptible contacts:

• Dose: 0.5 mL/kg IM (maximum 15 mL) 6, 1
• Timing: Within 6 days of exposure 1
• Special consideration: Immunocompromised patients should receive IG regardless of vaccination status 2

For recipients of regular IGIV therapy:

• At least 100 mg/kg within 3 weeks before exposure provides adequate protection 6, 1
• If exposed >3 weeks after IGIV dose, consider an additional dose 6

Critical timing consideration: After IG administration, delay measles vaccination for 5-6 months to avoid interference from passively acquired antibodies. 1 Live measles vaccine should be given 3 months after IG administration. 6

Important caveat: Do not use immune globulin for outbreak control—it is indicated only for individual post-exposure prophylaxis. 1 Post-exposure vaccination or IG administration is not completely effective; exposed medical personnel should be removed from patient contact days 5-21 after exposure. 6

Special Populations Requiring Enhanced Management

Pregnant Women

• Administer IG 0.25 mL/kg (maximum 15 mL) within 6 days of exposure if not yet symptomatic 1
• Once symptomatic, provide supportive care with vitamin A supplementation 1
• Measles vaccine is contraindicated during pregnancy 6

Immunocompromised Patients

• Administer IG 0.5 mL/kg (maximum 15 mL) if exposed, regardless of vaccination status 2
• Severely immunocompromised HIV-infected patients show diminished antibody response to measles vaccine 6
• Measles vaccine is contraindicated in persons immunocompromised due to immune deficiency diseases, leukemia, lymphoma, generalized malignancy, or immunosuppressive therapy 6

Infants <12 Months

• For household contacts ≥6 months exposed to measles: MMR vaccine within 72 hours is acceptable 6
• Infants vaccinated before age 12 months must be revaccinated on or after the first birthday with two doses of MMR separated by at least 28 days 6
• For infants who cannot receive vaccine: IG 0.25 mL/kg (maximum 15 mL) within 6 days 1

Outbreak Control Measures

During measles outbreaks in healthcare facilities, schools, or colleges:

• All persons born in 1957 or later without evidence of two doses of measles vaccine or other evidence of immunity should receive one dose immediately 6
• Second dose should be administered not less than 1 month later 6
• Vaccination of older employees (born before 1957) with occupational exposure should also be considered during outbreaks 6
• Identify and manage contacts immediately, including vaccinating or excluding persons without acceptable evidence of immunity 2

Exception for resource-limited settings: In emergency refugee-camp outbreak situations where isolation resources are unavailable, prioritize mass vaccination over isolation; airborne isolation is not required in such contexts. 1